LRLaura G. Rosen

Laura G. Rosen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laura G. Rosen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Steven R. Laviolette

    Addiction Research Group, Schulich School of Medicine & Dentistry, Western University, London, Canada

    5 shared publications
  • Jordan Zunder

    Addiction Research Group, Department of Anatomy and Cell Biology, and

    3 shared publications
  • Justine Renard

    Canadian Centre on Substance Use and Addiction, Ottawa, Canada

    3 shared publications
  • Walter Rushlow

    Addiction Research Group, Schulich School of Medicine and Dentistry, University of Western Ontario London, ON, Canada ; Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario London, ON, Canada ; Department of Psychiatry, Schulich School of Medicine and Dentistry, University of Western Ontario London, ON, Canada

    3 shared publications
  • Hans C. Dringenberg

    Department of Psychology, Queen's University, Kingston, Ontario K7L 3N6, Canada

    2 shared publications
  • Walter J. Rushlow

    Addiction Research Group, Department of Anatomy and Cell Biology, and Department of Psychiatry, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario N6A 5C1, Canada

    2 shared publications

Latest Publications

  • Open Access

    Perceptions and behaviours surrounding cannabis use during pregnancy, breastfeeding, and early parenting in Canada: a qualitative study

    by Justine Renard, Llisa Morrow, Jaismin Kaur Harneja, Laura G. Rosen

    Background: Cannabis use during pregnancy, breastfeeding and early parenting raises important public health concerns due to potential impacts on fetal and child development as well as parental health. However, individuals who use cannabis during these periods remain underrepresented in research. This study examines perceptions, behaviours, and decision-making related to cannabis use during pregnancy, breastfeeding, and early parenthood in Canada. Methods: A qualitative descriptive study was conducted using in-depth, semi-structured interviews. Thirty-one women aged 18–55 years were recruited across Canada. Eligible participants had used cannabis at least once in the past 10 years and reported experience with pregnancy, breastfeeding, or caring for a child under three years of age. Participants represented five Canadian regions and included English- and French-speaking individuals. Interviews were conducted online between April and May 2025, audio-recorded, transcribed verbatim, and analyzed using thematic analysis. Results: Analysis identified key themes related to: motivations for cannabis use, product types and modes of consumption, perceived health effects and benefits, interactions with healthcare providers, knowledge gaps, information sources, and experiences of stigma. Participants described having to weigh known benefits of cannabis against uncertain risks to unborn or young children in the context of receiving limited and inconsistent clinical guidance. Challenges disclosing cannabis use to healthcare providers contributed to seeking information from informal or non-clinical sources of information. Conclusions: This study addresses critical gaps in understanding cannabis use during pregnancy, breastfeeding, and early parenting in Canada. Findings highlight the need for clear, evidence-informed, and non-judgmental public health messaging and clinical communication to support informed decision-making and harm reduction among those who are pregnant, breastfeeding, and parenting young children.

  • Open Access

    Understanding Healthcare Professionals’ Perspectives on Cannabis for Medical Purposes in Canada: A Scoping Review

    by Justine Renard, Marta De Felice, Katarina Kane, Laura G. Rosen

    Background: The legalization of recreational cannabis in Canada has raised significant challenges for healthcare providers (HCPs), who are increasingly requested to navigate conversations with patients about cannabis use, effects, benefits, and risks. Summary: This scoping review aimed to: (1) identify HCP knowledge gaps and barriers related to medical cannabis use; (2) explore their perceptions and practices surrounding medical cannabis use in healthcare; and (3) assess HCP education and training needs. A search of PubMed, PsycNet, CINAHL, and grey literature identified 240 studies published between October 2018 and March 2026 that focused on Canadian HCP views, practices, challenges and needs related to medical cannabis. Of 187 articles screened, 26 met inclusion criteria. HCP-endorsed uses for medical cannabis were primarily for treatment of oncological nausea pain, chronic pain, and pediatric epilepsy. Many HCPs remain hesitant to consider cannabis in their treatment plans due to limited knowledge and training, stigma, regulatory challenges, cost, and insufficient clinical evidence. Across studies, HCPs expressed a strong desire for more formal cannabis education and clearer regulatory and institutional guidance. Key Messages: HCPs in Canada remain cautious about integrating cannabis into clinical care, citing safety concerns, limited clinical evidence, and systemic barriers. Addressing these challenges through targeted education and clearer clinical guidance may help build HCP confidence and support safer, evidence-informed patient care.

  • Open Access

    Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway

    by Justine Renard, Michael Loureiro, Laura G. Rosen, Jordan Zunder, Cleusa de Oliveira, Susanne Schmid, Walter J. Rushlow, Steven R. Laviolette

    Schizophrenia-related psychosis is associated with disturbances in mesolimbic dopamine (DA) transmission, characterized by hyperdopaminergic activity in the mesolimbic pathway. Currently, the only clinically effective treatment for schizophrenia involves the use of antipsychotic medications that block DA receptor transmission. However, these medications produce serious side effects leading to poor compliance and treatment outcomes. Emerging evidence points to the involvement of a specific phytochemical component of marijuana called cannabidiol (CBD), which possesses promising therapeutic properties for the treatment of schizophrenia-related psychoses. However, the neuronal and molecular mechanisms through which CBD may exert these effects are entirely unknown. We used amphetamine (AMPH)-induced sensitization and sensorimotor gating in rats, two preclinical procedures relevant to schizophrenia-related psychopathology, combined within vivosingle-unit neuronal electrophysiology recordings in the ventral tegmental area, and molecular analyses to characterize the actions of CBD directly in the nucleus accumbens shell (NASh), a brain region that is the current target of most effective antipsychotics. We demonstrate that Intra-NASh CBD attenuates AMPH-induced sensitization, both in terms of DAergic neuronal activity measured in the ventral tegmental area and psychotomimetic behavioral analyses. We further report that CBD controls downstream phosphorylation of the mTOR/p70S6 kinase signaling pathways directly within the NASh. Our findings demonstrate a novel mechanism for the putative antipsychotic-like properties of CBD in the mesolimbic circuitry. We identify the molecular signaling pathways through which CBD may functionally reduce schizophrenia-like neuropsychopathology.SIGNIFICANCE STATEMENTThe cannabis-derived phytochemical, cannabidiol (CBD), has been shown to have pharmacotherapeutic efficacy for the treatment of schizophrenia. However, the mechanisms by which CBD may produce antipsychotic effects are entirely unknown. Using preclinical behavioral procedures combined with molecular analyses andin vivoneuronal electrophysiology, our findings identify a functional role for the nucleus accumbens as a critical brain region whereby CBD can produce effects similar to antipsychotic medications by triggering molecular signaling pathways associated with the effects of classic antipsychotic medications. Specifically, we report that CBD can attenuate both behavioral and dopaminergic neuronal correlates of mesolimbic dopaminergic sensitization, via a direct interaction with mTOR/p70S6 kinase signaling within the mesolimbic pathway.


  • Open Access

    Molecular and neuronal plasticity mechanisms in the amygdala-prefrontal cortical circuit: implications for opiate addiction memory formation

    by Laura G. Rosen, Ninglei Sun, Walter Rushlow, Steven R. Laviolette

    The persistence of associative memories linked to the rewarding properties of drugs of abuse is a core underlying feature of the addiction process. Opiate class drugs in particular, possess potent euphorigenic effects which, when linked to environmental cues, can produce drug-related ‘trigger’ memories that may persist for lengthy periods of time, even during abstinence, in both humans and other animals. Furthermore, the transitional switch from the drug-naïve, non-dependent state to states of dependence and withdrawal, represents a critical boundary between distinct neuronal and molecular substrates associated with opiate-reward memory formation. Identifying the functional molecular and neuronal mechanisms related to the acquisition, consolidation, recall and extinction phases of opiate-related reward memories is critical for understanding, and potentially reversing, addiction-related memory plasticity characteristic of compulsive drug-seeking behaviors. The mammalian prefrontal cortex (PFC) and basolateral nucleus of the amygdala (BLA) share important functional and anatomical connections that are involved importantly in the processing of associative memories linked to drug reward. In addition, both regions share interconnections with the mesolimbic pathway’s ventral tegmental area (VTA) and nucleus accumbens (NAc) and can modulate dopamine (DA) transmission and neuronal activity associated with drug-related DAergic signaling dynamics. In this review, we will summarize research from both human and animal modelling studies highlighting the importance of neuronal and molecular plasticity mechanisms within this circuitry during critical phases of opiate addiction-related learning and memory processing. Specifically, we will focus on two molecular signaling pathways known to be involved in both drug-related neuroadaptations and in memory-related plasticity mechanisms; the extracellular-signal-regulated kinase system (ERK) and the Ca2+/calmodulin-dependent protein kinases (CaMK). Evidence will be reviewed that points to the importance of critical molecular memory switches within the mammalian brain that might mediate the neuropathological adaptations resulting from chronic opiate exposure, dependence and withdrawal.


  • Opiate Exposure State Controls a D2-CaMKIIα-Dependent Memory Switch in the Amygdala-Prefrontal Cortical Circuit

    by Laura G Rosen, Jordan Zunder, Justine Renard, Jennifer Fu, Walter Rushlow, Steven R Laviolette

    The mammalian basolateral amygdala (BLA) and medial prefrontal cortex (mPFC) comprise a functionally interconnected circuit that is critical for processing opiate-related associative memories. In the opiate-naïve state, reward memory formation in the BLA involves a functional link between dopamine (DA) D1 receptor (D1R) and extracellular signal-related kinase 1/2 (ERK1/2) signaling substrates, but switches to a DA D2 (D2R)/Ca(2+)/calmodulin-dependent protein kinase IIα (CaMKIIα)-dependent memory substrate following chronic opiate exposure and spontaneous withdrawal. Using conditioned place preference (CPP) in rats paired with molecular analyses, we examined the role of intra-mPFC CaMKII, ERK and DAergic activity during the formation of opiate associative memories, and how opiate exposure state may regulate the functions of these molecular memory pathways. We report that the role of CaMKIIα signaling is functionally reversed within the BLA-mPFC pathway depending on opiate exposure state. Thus, in the opiate-naïve state, intra-mPFC but not intra-BLA blockade of CaMKII signaling prevents formation of opiate reward memory. However, following chronic opiate exposure and spontaneous withdrawal, the role of CaMKII signaling in the BLA-mPFC is functionally reversed. This behavioral memory switch corresponds to a selective increase in the expression of D2R and CaMKIIα, but not other calcium/calmodulin-related molecules, nor D1R expression levels within the mPFC.


  • Structure and characteristics of community‐based multidisciplinary wound care teams in Ontario: An environmental scan

    by Lusine Abrahamyan, Josephine Wong, Ba' Pham, Gina Trubiani, Steven Carcone, Nicholas Mitsakakis Msc, Laura Rosen, Valeria E. Rac, Murray Krahn

    Multidisciplinary team approach is an essential component of evidence‐based wound management in the community. The objective of this study was to identify and describe community‐based multidisciplinary wound care teams in Ontario. For the study, a working definition of a multidisciplinary wound care team was developed, and a two‐phase field evaluation was conducted. In phase I, a systematic survey with three search strategies (environmental scan) was conducted to identify all multidisciplinary wound care teams in Ontario. In phase II, the team leads were surveyed about the service models of the teams. We identified 49 wound care teams in Ontario. The highest ratio of Ontario seniors to wound team within each Ontario health planning region was 82,358:1; the lowest ratio was 14,151:1. Forty‐four teams (90%) participated in the survey. The majority of teams existed for at least 5 years, were established as hospital outpatient clinics, and served patients with chronic wounds. Teams were heterogeneous in on‐site capacity of specialized diagnostic testing and wound treatment, team size, and patient volume. Seventy‐seven percent of teams had members from three or more disciplines. Several teams lacked essential disciplines. More research is needed to identify optimal service models leading to improved patient outcomes.


  • NMDA Receptor Blockade in the Prelimbic Cortex Activates the Mesolimbic System and Dopamine-Dependent Opiate Reward Signaling

    by Addiction Research Group, Huibing Tan, Laura G. Rosen, Garye A. Ng, Walter J. Rushlow, Steven R. Laviolette

    N-Methyl-d-aspartate (NMDA) receptors in the medial prefrontal cortex (mPFC) are involved in opiate reward processing and modulate sub-cortical dopamine (DA) activity. NMDA receptor blockade in the prelimbic (PLC) division of the mPFC strongly potentiates the rewarding behavioural properties of normally sub-reward threshold doses of opiates. However, the possible functional interactions between cortical NMDA and sub-cortical DAergic motivational neural pathways underlying these effects are not understood. This study examines how NMDA receptor modulation in the PLC influences opiate reward processing via interactions with sub-cortical DAergic transmission. We further examined whether direct intra-PLC NMDA receptor modulation may activate DA-dependent opiate reward signaling via interactions with the ventral tegmental area (VTA). Using an unbiased place conditioning procedure (CPP) in rats, we performed bilateral intra-PLC microinfusions of the competitive NMDA receptor antagonist, (2R)-amino-5-phosphonovaleric acid (AP-5), prior to behavioural morphine place conditioning and challenged the rewarding effects of morphine with DA receptor blockade. We next examined the effects of intra-PLC NMDA receptor blockade on the spontaneous activity patterns of presumptive VTA DA or GABAergic neurons, using single-unit, extracellular in vivo neuronal recordings. We show that intra-PLC NMDA receptor blockade strongly activates sub-cortical DA neurons within the VTA while inhibiting presumptive non-DA GABAergic neurons. Behaviourally, NMDA receptor blockade activates a DA-dependent opiate reward system, as pharmacological blockade of DA transmission blocked morphine reward only in the presence of intra-PLC NMDA receptor antagonism. These findings demonstrate a cortical NMDA-mediated mechanism controlling mesolimbic DAergic modulation of opiate reward processing.


  • Open Access

    Opiate Exposure and Withdrawal Induces a Molecular Memory Switch in the Basolateral Amygdala between ERK1/2 and CaMKIIα-Dependent Signaling Substrates

    by Danika Lyons, Xavier de Jaeger, Laura G. Rosen, Tasha Ahmad, Nicole M. Lauzon, Jordan Zunder, Lique M. Coolen, Walter Rushlow, Steven R. Laviolette

    Opiate reward memories are powerful triggers for compulsive opiate-seeking behaviors. The basolateral amygdala (BLA) is an important structure for the processing of opiate-related associative memories and is functionally linked to the mesolimbic dopamine (DA) pathway. Transmission through intra-BLA DA D1-like and D2-like receptors independently modulates the formation of opiate reward memories as a function of opiate-exposure state. Thus, in the opiate-naive state, intra-BLA D1 transmission is required for opiate-related memory formation. Once opiate dependence and withdrawal has developed, a functional switch to a DA D2-mediated memory mechanism takes place. However, the downstream molecular signaling events that control this functional switch between intra-BLA DA D1 versus D2 receptor transmission are not currently understood. Using an unbiased place conditioning procedure in rats combined with molecular analyses, we report that opiate reward memory acquisition requires intra-BLA ERK1/2 signaling only in the previously opiate-naive state. However, following chronic opiate exposure and withdrawal, intra-BLA reward memory processing switches to a CaMKIIα-dependent memory substrate. Furthermore, the ability of intra-BLA DA D1 or D2 receptor transmission to modulate the motivational salience of opiates similarly operates through a D1-mediated ERK-dependent mechanism in the opiate-naive state, but switches to a D2-mediated CaMKIIα-dependent mechanism in the dependent/withdrawn state. Protein analysis of BLA tissue revealed a downregulation of ERK1/2 phosphorylation and a dramatic reduction in both total and phosphorylated CaMKIIα signaling, specifically in the opiate-dependent/withdrawn state, demonstrating functional control of ERK1/2-dependent versus CaMKIIα-dependent memory mechanisms within the BLA, controlled by opiate-exposure state.


  • Open Access

    Occlusion of Low-Frequency-Induced, Heterosynaptic Long-Term Potentiation in the Rat Hippocampus In Vivo Following Spatial Training

    by Diala Habib, Claudia K.Y. Tsui, Laura G. Rosen, Hans C. Dringenberg

    Recent work has shown that some low-frequency stimulation (LFS) protocols can induce long-term potentiation (LTP) at hippocampal synapses. As LFS mimics certain aspects of low-frequency oscillations during slow-wave sleep, LFS-LTP may be relevant to processes of sleep-dependent consolidation. Here, alternating LFS (1 Hz) of heterosynaptic inputs arising in the medial septum and area CA3 induced LTP at hippocampal CA1 synapses of anesthetized rats. Remarkably, this LTP was absent when delivered 3 h, but not 8 or 24 h, after training in the hidden platform version of the Morris water maze, suggesting a time-specific occlusion of LFS-LTP following spatial learning. LTP assessed 3 h after training was intact in yoked swim controls and rats trained in darkness. Visible platform training resulted in heterogeneous effects, with about half of the animals showing LTP occlusion. Pharmacological experiments revealed that N-methyl-d-aspartate (NMDA)-receptor activation was required for both LFS-LTP and the retention of spatial learning. To test whether a learning-related, NMDA-dependent potentiation accounted for the occlusion effect, we blocked NMDA receptors immediately following spatial training. This manipulation reversed LTP occlusion 3 h after training. Together, these experiments indicate a mechanistic overlap between heterosynaptically induced LFS-LTP and processes mediating the consolidation of spatial information at hippocampal synapses.